Trial reportRheumatology (Oxford, England)2016
Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Trial report in Rheumatology (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Using B-cell-targeting drugs to achieve marked efficacy in anti-signal recognition particle myopathy: two case reports.Immunologic research · 2026Article
- B cells in anti-tRNA synthetase syndrome patients show an activated, interferon-responsive signature.Frontiers in immunology · 2026Article
- Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational study.Rheumatology (Oxford, England) · 2025Observational
- TLR7/8 Activation in Immune Cells and Muscle by RNA-Containing Immune Complexes: Role in Inflammation and the Pathogenesis of Myositis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Peripheral Blood Lymphocyte Subsets and Heterogeneity of B Cell Subsets in Patients of Idiopathic Inflammatory Myositis with Different Myositis-specific Autoantibodies.Inflammation · 2025Article
- Successful treatment of anti-signal recognition particle antibody-positive myositis with intravenous cyclophosphamide: A case report.Fukushima journal of medical science · 2025Article
- Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies.Frontiers in immunology · 2025Review
- Relationship between Jo-1 B Cell Epitope Profile and Clinical Features of Anti-Synthetase Syndrome.ACR open rheumatology · 2024Article
- Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies.Arthritis research & therapy · 2024Article
- Sample Size Calculation for an Individual Stepped-Wedge Randomized Trial.Biometrical journal. Biometrische Zeitschrift · 2024Article
- Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains.Rheumatology (Oxford, England) · 2024Article
- Quantification of autoantibodies using a luminescent profiling method in autoimmune interstitial lung disease.Frontiers in immunology · 2024Article
- B cell receptor repertoire abnormalities in autoimmune disease.Frontiers in immunology · 2024Review
- Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome.Arthritis research & therapy · 2023Article
- B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2023Article
- Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.Nature reviews. Rheumatology · 2023Review
- TCRβ clones in muscle tissue share structural features in patients with idiopathic inflammatory myopathy and are associated with disease activity.Frontiers in immunology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesTo determine the longitudinal trends in serum levels of four myositis-associated autoantibodies: anti-Jo-1, -transcription intermediary factor 1 γ (TIF1-γ), -signal recognition particle (SRP) and -Mi-2, after B cell depletion with rituximab, and to determine the longitudinal association of these autoantibody levels with disease activity as measured by myositis core-set measures (CSMs).
methodsTreatment-resistant adult and pediatric myositis subjects (n = 200) received rituximab in the 44-week Rituximab in Myositis Trial. CSMs [muscle enzymes, manual muscle testing (MMT), physician and patient global disease activity, HAQ, and extramuscular disease activity] were evaluated monthly and anti-Jo-1 (n = 28), -TIF1-γ (n = 23), -SRP (n = 25) and -Mi-2 (n = 26) serum levels were measured using validated quantitative ELISAs. Temporal trends and the longitudinal relationship between myositis-associated autoantibodies levels and CSM were estimated using linear mixed models.
resultsFollowing rituximab, anti-Jo-1 levels decreased over time (P < 0.001) and strongly correlated with all CSMs (P < 0.008). Anti-TIF1-γ levels also decreased over time (P < 0.001) and were only associated with HAQ, MMT and physician and patient global disease activity. Anti-SRP levels did not change significantly over time, but were significantly associated with serum muscle enzymes. Anti-Mi-2 levels significantly decreased over time and were associated with muscle enzymes, MMT and the physician global score.
conclusionAnti-Jo-1, anti-TIF1-γ and anti-Mi-2 levels in myositis subjects decreased after B cell depletion and were correlated with changes in disease activity, whereas anti-SRP levels were only associated with longitudinal muscle enzyme levels. The strong association of anti-Jo-1 levels with clinical outcomes suggests that anti-Jo-1 autoantibodies may be a good biomarker for disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.